TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04252885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir and Ritonavir Tablets
Description: As indicated in arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol
Description: As indicated in arm/group descriptions
Study: NCT03064048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Neo-ASA
Description: Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
Study: NCT03212859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach2Move
Description: Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~* Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~* Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~* The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~* In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care physiotherapy among older adults:~* Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~* Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~* Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~* Collaborate with other disciplines in a multidisciplinary context.
Study: NCT04642417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary fiber literacy
Description: education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine care
Description: routine care
Study: NCT02816073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pan-retinal photocoagulation using pattern scanning laser
Description: Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pan-retinal photocoagulation using pattern scanning laser
Description: Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
Study: NCT02693262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS Mode on Biotronik CRT-D
Description: Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer Mode on Biotronik CRT-D
Description: Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
Study: NCT03157076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)
Description: The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)
Description: The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
Study: NCT01073826

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sport

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sport

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sport

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Study: NCT00563914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferroquine (SSR97193)
Description: associated with artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine
Description: associated with artesunate
Study: NCT02826161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
Study: NCT03895203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimekizumab
Description: Subjects will receive bimekizumab at pre-specified time-points.
Study: NCT02826161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m\^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
Study: NCT04094779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual relation care
Description: When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual relation care
Description: When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flash activity breath of fresh air
Description: When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
Study: NCT03638141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Cohort A dose)
Description: Tremelimumab IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab (Cohort B dose)
Description: Tremelimumab IV
Study: NCT03131726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: see arm description
Study: NCT01407263

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph node template
Description: Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence. .No lymph nodes will be removed in patients randomized to the no PLND arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse versus vertical closure
Description: Transverse versus vertical closure of the port site incision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antibiotic prophylaxis
Description: One vs. three days of antibiotic prophylaxis at catheter removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemostatic Agent
Description: For the patients randomized to routine indwelling HA agent use, the operating surgeon may choose to use either Surgicel™, Surgicel SNoW™, Arista™, FloSeal or surgeon's choice HA directed at the prostatic fossa, ligated dorsal vein complex, or neurovascular bundles. Because there is no standard HA or method of application, the surgeon will apply the HA according to the surgeon's experience and document both the HA used, and the location applied in the operative report. For patients randomized to no routine indwelling HA use, surgeons will only apply a HA if they are unable to achieve hemostasis using traditional means or feel it would be unsafe to complete the operation without using a HA for additional hemostasis. Providers in either arm may use HA as needed provided the intention is not to leave the HA indwelling.
Study: NCT01930916

Intervention type: DEVICE
Group type: OTHER
Intervention: INR capillary measurement with INRatio 2 device
Description: INR capillary measurement with INRatio 2 device

Intervention type: OTHER
Group type: OTHER
Intervention: antiphospholipid antibodies and lupus anticoagulant
Description: Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
Study: NCT02003755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.
Study: NCT04084002

Intervention type: OTHER
Intervention: physical activity measurement
Description: Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)

Intervention type: OTHER
Intervention: physical activity measurement
Description: Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
Study: NCT02954328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
Study: NCT01263717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tesamorelin
Description: Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
Study: NCT02006199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness meditation
Description: 8 weeks of mindfulness meditation specified for OCD patient

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness meditation
Description: 8 weeks of mindfulness meditation specified for OCD patient
Study: NCT01543802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
Study: NCT00551174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronate [Bonviva/Boniva]
Description: 3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronate [Bonviva/Boniva]
Description: 2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
Study: NCT01534416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
Study: NCT00205660

Intervention type: OTHER
Group type: OTHER
Intervention: Stayers
Description: Participants remain on their current antipsychotic.

Intervention type: OTHER
Group type: OTHER
Intervention: Switchers
Description: Subjects are randomized to switch to aripiprazole from their current antipsychotic.
Study: NCT03099603

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTD1801
Description: A small molecular compound for the treatment of primary sclerosing cholangitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTD1801
Description: A small molecular compound for the treatment of primary sclerosing cholangitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTD1801
Description: A small molecular compound for the treatment of primary sclerosing cholangitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTD1801
Description: A small molecular compound for the treatment of primary sclerosing cholangitis
Study: NCT02709837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional
Study: NCT03486405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
Study: NCT00622102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery arm (Lottery and Med-eMonitor)
Description: Lottery and Med-eMonitor

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Lottery (Med-eMonitor only)
Description: Med-eMonitor only
Study: NCT04716374

Intervention type: OTHER
Intervention: Tumor molecular profiling
Description: Tumor tissue processing and all NGS genotyping were performed at the Laboratory of Molecular Oncology (Hellenic Foundation for Cancer Research / AUTH). Paraffin H\&E sections from the retrieved tissue blocks were centrally reviewed for tumor histology and tissue adequacy for DNA extraction and were marked for macrodissection along with tumor DNA content \[(former tumor cell content (TCC%)\] assessment. DNA was extracted from macrodissected tissue fragments with the QIAamp® DNA mini kit (Qiagen, Hilden, Germany), measured in a Qubit fluorometer (Thermo Fisher Scientific, Paisley, UK), and genotyped with NGS in an Ion Torrent Proton sequencer (Thermo Fisher Scientific) by using a previously published custom panel (Kotoula, Lakis et al. 2019). Following stringent variant quality filtering (Kotoula, Chatzopoulos et al. 2021), 500 tumors
Study: NCT03163316

Intervention type: OTHER
Intervention: Unenhanced magnetic resonance imaging.
Description: The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination.
Study: NCT02008136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxins
Description: intramuscular injections
Study: NCT04530929

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SANPROBI BARRIER
Description: Competitors used probiotic for three months at a dose of 2x2 capsules daily (2.5 x 109 CFU / g (1 capsule)).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Competitors used placebo for three months at a dose of 2x2 capsules daily.
Study: NCT01514110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Pharmacology of RAD001 as a combination partner for conventional agents.
Study: NCT00672607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extracts of Vitex agnus castus tablets
Description: orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02638974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Skin Camouflage
Description: Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
Study: NCT02186977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAX-ID
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAX-ID
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
Description: 1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)
Description: 0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
Study: NCT05680428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early feeding
Description: oral feeding within 12hours after stoma reversal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional feeding
Description: oral feeding after 48hours of NBM after stoma reversal
Study: NCT02454010

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FF21101
Description: (90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
Study: NCT02204345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5479599
Description: RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
Study: NCT04156893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red cell units that are genotype matched at the RHD and RHCE loci
Description: Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
Study: NCT00186485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim
Description: The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
Study: NCT03305692

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optimization of CRT Device
Description: Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Optimization of CRT Device
Description: Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
Study: NCT03895203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab will be administered according to the labeling recommendations.
Study: NCT03698539

Intervention type: BEHAVIORAL
Intervention: hand gestures
Description: We observe the use of spontaneous hand gestures in all the groups.

Intervention type: BEHAVIORAL
Intervention: hand gestures
Description: We observe the use of spontaneous hand gestures in all the groups.

Intervention type: BEHAVIORAL
Intervention: hand gestures
Description: We observe the use of spontaneous hand gestures in all the groups.

Intervention type: BEHAVIORAL
Intervention: hand gestures
Description: We observe the use of spontaneous hand gestures in all the groups.